{"slug":"cancers-least-served","title":"Cancers with most trials per approved product","basis":"Cancers with at least ten trials, excluding umbrella records that other cancers name as their parent, ordered by trials divided by approved products, with cancers that have no approved product first.","metric":"Trials per approved product","context":"Trials and approved products","how":"For each cancer with ten or more trial records, divides the trial count by the number of products with status approved that list the cancer. Cancers with no approved product cannot be divided and are placed first, ordered by their trial count. The ten-trial floor keeps a cancer with one trial and no product from topping the table, and umbrella records (any cancer that another cancer record names as its parent) are left out because their approvals sit on the subtypes.","coverage":{"filled":3585,"of":3596,"what":"trials name at least one cancer","share":0.997},"total":60,"top":50,"rows":[{"rank":1,"id":"metastatic-cancer","name":"Metastatic cancer (cancer that has spread)","kind":"cancer","route":"/cancers/metastatic-cancer/","value":1000563,"metric":"no approved product","context":"563 trials, 0 approved products"},{"rank":2,"id":"oesophageal-squamous-cell-carcinoma","name":"Oesophageal squamous cell carcinoma","kind":"cancer","route":"/cancers/oesophageal-squamous-cell-carcinoma/","value":1000014,"metric":"no approved product","context":"14 trials, 0 approved products"},{"rank":3,"id":"resectable-pdac","name":"Resectable pancreatic ductal adenocarcinoma","kind":"cancer","route":"/cancers/resectable-pdac/","value":1000011,"metric":"no approved product","context":"11 trials, 0 approved products"},{"rank":4,"id":"hpv-positive-oropharyngeal-cancer","name":"HPV-positive oropharyngeal cancer","kind":"cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","value":1000010,"metric":"no approved product","context":"10 trials, 0 approved products"},{"rank":5,"id":"metastatic-pdac","name":"Metastatic pancreatic ductal adenocarcinoma","kind":"cancer","route":"/cancers/metastatic-pdac/","value":31,"metric":"31","context":"62 trials, 2 approved products"},{"rank":6,"id":"muscle-invasive-bladder-cancer","name":"Muscle-invasive and advanced bladder cancer","kind":"cancer","route":"/cancers/muscle-invasive-bladder-cancer/","value":24.5,"metric":"24.5","context":"49 trials, 2 approved products"},{"rank":7,"id":"prostate-high-risk","name":"Localised prostate cancer, high and very high risk","kind":"cancer","route":"/cancers/prostate-high-risk/","value":12,"metric":"12","context":"12 trials, 1 approved product"},{"rank":8,"id":"rectal-cancer","name":"Rectal cancer","kind":"cancer","route":"/cancers/rectal-cancer/","value":12,"metric":"12","context":"12 trials, 1 approved product"},{"rank":9,"id":"non-muscle-invasive-bladder-cancer","name":"Non-muscle-invasive bladder cancer","kind":"cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","value":11.333333333333334,"metric":"11.3","context":"34 trials, 3 approved products"},{"rank":10,"id":"platinum-resistant-ovarian-cancer","name":"Platinum-resistant ovarian cancer","kind":"cancer","route":"/cancers/platinum-resistant-ovarian-cancer/","value":10.666666666666666,"metric":"10.7","context":"32 trials, 3 approved products"},{"rank":11,"id":"gastric-her2-positive","name":"HER2-positive gastric cancer","kind":"cancer","route":"/cancers/gastric-her2-positive/","value":10,"metric":"10","context":"20 trials, 2 approved products"},{"rank":12,"id":"recurrent-metastatic-hnscc","name":"Recurrent or metastatic head and neck squamous cell carcinoma","kind":"cancer","route":"/cancers/recurrent-metastatic-hnscc/","value":9.5,"metric":"9.5","context":"38 trials, 4 approved products"},{"rank":13,"id":"egfr-mutant-nsclc","name":"EGFR-mutated non-small-cell lung cancer","kind":"cancer","route":"/cancers/egfr-mutant-nsclc/","value":9.4,"metric":"9.4","context":"94 trials, 10 approved products"},{"rank":14,"id":"cll-relapsed","name":"Relapsed or refractory chronic lymphocytic leukaemia","kind":"cancer","route":"/cancers/cll-relapsed/","value":9,"metric":"9","context":"27 trials, 3 approved products"},{"rank":15,"id":"resectable-nsclc","name":"Resectable stage I to III non-small-cell lung cancer","kind":"cancer","route":"/cancers/resectable-nsclc/","value":9,"metric":"9","context":"54 trials, 6 approved products"},{"rank":16,"id":"myeloma-relapsed-refractory","name":"Relapsed or refractory multiple myeloma","kind":"cancer","route":"/cancers/myeloma-relapsed-refractory/","value":8.1,"metric":"8.1","context":"81 trials, 10 approved products"},{"rank":17,"id":"kras-g12c-nsclc","name":"KRAS G12C-mutant non-small-cell lung cancer","kind":"cancer","route":"/cancers/kras-g12c-nsclc/","value":8,"metric":"8","context":"32 trials, 4 approved products"},{"rank":18,"id":"uveal-melanoma","name":"Uveal melanoma","kind":"cancer","route":"/cancers/uveal-melanoma/","value":8,"metric":"8","context":"16 trials, 2 approved products"},{"rank":19,"id":"prostate-mcrpc","name":"Metastatic castration-resistant prostate cancer","kind":"cancer","route":"/cancers/prostate-mcrpc/","value":7.4,"metric":"7.4","context":"74 trials, 10 approved products"},{"rank":20,"id":"recurrent-metastatic-cervical-cancer","name":"Recurrent or metastatic cervical cancer","kind":"cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/","value":7.333333333333333,"metric":"7.3","context":"22 trials, 3 approved products"},{"rank":21,"id":"oesophageal-adenocarcinoma","name":"Oesophageal and junctional adenocarcinoma","kind":"cancer","route":"/cancers/oesophageal-adenocarcinoma/","value":7,"metric":"7","context":"14 trials, 2 approved products"},{"rank":22,"id":"stage-iii-unresectable-nsclc","name":"Unresectable stage III non-small-cell lung cancer","kind":"cancer","route":"/cancers/stage-iii-unresectable-nsclc/","value":7,"metric":"7","context":"14 trials, 2 approved products"},{"rank":23,"id":"advanced-recurrent-endometrial-cancer","name":"Advanced or recurrent endometrial cancer","kind":"cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/","value":6.666666666666667,"metric":"6.7","context":"20 trials, 3 approved products"},{"rank":24,"id":"kras-g12c-colorectal","name":"KRAS G12C-mutant colorectal cancer","kind":"cancer","route":"/cancers/kras-g12c-colorectal/","value":6.5,"metric":"6.5","context":"13 trials, 2 approved products"},{"rank":25,"id":"follicular-lymphoma","name":"Follicular lymphoma","kind":"cancer","route":"/cancers/follicular-lymphoma/","value":6.428571428571429,"metric":"6.4","context":"45 trials, 7 approved products"},{"rank":26,"id":"tnbc-metastatic","name":"Metastatic triple-negative breast cancer","kind":"cancer","route":"/cancers/tnbc-metastatic/","value":6.333333333333333,"metric":"6.3","context":"38 trials, 6 approved products"},{"rank":27,"id":"her2-mutant-nsclc","name":"HER2-mutant non-small-cell lung cancer","kind":"cancer","route":"/cancers/her2-mutant-nsclc/","value":6.25,"metric":"6.3","context":"25 trials, 4 approved products"},{"rank":28,"id":"platinum-sensitive-ovarian-cancer","name":"Platinum-sensitive ovarian cancer","kind":"cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/","value":6,"metric":"6","context":"18 trials, 3 approved products"},{"rank":29,"id":"hcc-advanced","name":"Advanced hepatocellular carcinoma (BCLC C)","kind":"cancer","route":"/cancers/hcc-advanced/","value":5.75,"metric":"5.8","context":"46 trials, 8 approved products"},{"rank":30,"id":"her2-positive-early-breast-cancer","name":"Early HER2-positive breast cancer","kind":"cancer","route":"/cancers/her2-positive-early-breast-cancer/","value":5.5,"metric":"5.5","context":"22 trials, 4 approved products"},{"rank":31,"id":"extensive-stage-sclc","name":"Extensive-stage small-cell lung cancer","kind":"cancer","route":"/cancers/extensive-stage-sclc/","value":5.375,"metric":"5.4","context":"43 trials, 8 approved products"},{"rank":32,"id":"cll-treatment-naive","name":"Chronic lymphocytic leukaemia, first treatment","kind":"cancer","route":"/cancers/cll-treatment-naive/","value":5.25,"metric":"5.3","context":"21 trials, 4 approved products"},{"rank":33,"id":"mantle-cell-lymphoma","name":"Mantle cell lymphoma","kind":"cancer","route":"/cancers/mantle-cell-lymphoma/","value":5.166666666666667,"metric":"5.2","context":"31 trials, 6 approved products"},{"rank":34,"id":"hcc-intermediate","name":"Intermediate hepatocellular carcinoma (BCLC B)","kind":"cancer","route":"/cancers/hcc-intermediate/","value":5,"metric":"5","context":"10 trials, 2 approved products"},{"rank":35,"id":"msi-high-colorectal","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","kind":"cancer","route":"/cancers/msi-high-colorectal/","value":4.75,"metric":"4.8","context":"19 trials, 4 approved products"},{"rank":36,"id":"pdl1-high-nsclc","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","kind":"cancer","route":"/cancers/pdl1-high-nsclc/","value":4.5,"metric":"4.5","context":"27 trials, 6 approved products"},{"rank":37,"id":"advanced-melanoma","name":"Advanced melanoma (unresectable stage III and stage IV)","kind":"cancer","route":"/cancers/advanced-melanoma/","value":4.083333333333333,"metric":"4.1","context":"49 trials, 12 approved products"},{"rank":38,"id":"clear-cell-rcc","name":"Clear cell renal cell carcinoma","kind":"cancer","route":"/cancers/clear-cell-rcc/","value":4,"metric":"4","context":"16 trials, 4 approved products"},{"rank":39,"id":"hr-positive-early-high-risk","name":"High-risk early HR-positive breast cancer","kind":"cancer","route":"/cancers/hr-positive-early-high-risk/","value":4,"metric":"4","context":"16 trials, 4 approved products"},{"rank":40,"id":"aml-older-unfit","name":"Acute myeloid leukaemia in older or unfit patients","kind":"cancer","route":"/cancers/aml-older-unfit/","value":3.6666666666666665,"metric":"3.7","context":"11 trials, 3 approved products"},{"rank":41,"id":"merkel-cell-carcinoma","name":"Merkel cell carcinoma","kind":"cancer","route":"/cancers/merkel-cell-carcinoma/","value":3.6666666666666665,"metric":"3.7","context":"11 trials, 3 approved products"},{"rank":42,"id":"high-grade-serous-ovarian-cancer","name":"High-grade serous ovarian cancer","kind":"cancer","route":"/cancers/high-grade-serous-ovarian-cancer/","value":3.5,"metric":"3.5","context":"14 trials, 4 approved products"},{"rank":43,"id":"tnbc-early","name":"Early triple-negative breast cancer","kind":"cancer","route":"/cancers/tnbc-early/","value":3.3333333333333335,"metric":"3.3","context":"10 trials, 3 approved products"},{"rank":44,"id":"polycythaemia-vera","name":"Polycythaemia vera (PV)","kind":"cancer","route":"/cancers/polycythaemia-vera/","value":3.25,"metric":"3.3","context":"13 trials, 4 approved products"},{"rank":45,"id":"primary-myelofibrosis","name":"Primary myelofibrosis","kind":"cancer","route":"/cancers/primary-myelofibrosis/","value":3.25,"metric":"3.3","context":"13 trials, 4 approved products"},{"rank":46,"id":"secondary-brain-tumours","name":"Brain metastases (secondary brain tumours)","kind":"cancer","route":"/cancers/secondary-brain-tumours/","value":3,"metric":"3","context":"12 trials, 4 approved products"},{"rank":47,"id":"prostate-mhspc","name":"Metastatic hormone-sensitive prostate cancer","kind":"cancer","route":"/cancers/prostate-mhspc/","value":3,"metric":"3","context":"21 trials, 7 approved products"},{"rank":48,"id":"recurrent-metastatic-nasopharyngeal-carcinoma","name":"Recurrent and metastatic nasopharyngeal carcinoma","kind":"cancer","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","value":3,"metric":"3","context":"12 trials, 4 approved products"},{"rank":49,"id":"osteosarcoma","name":"Osteosarcoma","kind":"cancer","route":"/cancers/osteosarcoma/","value":2.75,"metric":"2.8","context":"11 trials, 4 approved products"},{"rank":50,"id":"met-altered-nsclc","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","kind":"cancer","route":"/cancers/met-altered-nsclc/","value":2.7142857142857144,"metric":"2.7","context":"19 trials, 7 approved products"}]}